Literature DB >> 11598137

Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells.

S Wakino1, U Kintscher, Z Liu, S Kim, F Yin, M Ohba, T Kuroki, A H Schönthal, W A Hsueh, R E Law.   

Abstract

The cyclin-dependent kinase inhibitor p21(Cip1) is up-regulated in response to mitogenic stimulation in various cells. PPARgamma ligands troglitazone (TRO, 10 microm) and rosiglitazone (RSG, 10 microm) attenuated the induction of p21(Cip1) protein by platelet-derived growth factor (PDGF) and insulin without affecting cognate mRNA levels in rat aortic smooth muscle cells (RASMC). The protein kinase Cdelta (PKCdelta) inhibitor rottlerin also blocked the induction of p21(Cip1) protein, whereas the conventional PKC isotype inhibitor Gö 6976 had no effect. Kinetic studies using the protein synthesis inhibitor cycloheximide showed that TRO, RSG, and rottlerin shortened the half-life of p21(Cip1) protein. TRO, RSG, and rottlerin inhibited PDGF-induced expression of p21(Cip1), but they did not affect insulin-induced expression of p21(Cip1). Both ligands inhibited PKCdelta enzymatic activity in PDGF-stimulated RASMC but not in insulin-stimulated cells. Adenovirus-mediated overexpression of PKCdelta rescued the down-regulation of p21(Cip1) expression both by TRO and RSG in PDGF-treated RASMC. These data suggested that the PKCdelta pathway plays a critical role in PDGF-induced expression of p21(Cip1) in RASMC and may be the potential target for PPARgamma ligand effects. Src kinase-dependent tyrosine phosphorylation of PKCdelta was decreased substantially by TRO and RSG. Tyrosine phosphorylation and activation of c-Src in response to PDGF were unaffected by either PPARgamma ligand. Protein-tyrosine-phosphatase inhibitors sodium orthovanadate and dephostatin prevented PPARgamma ligand effects on PKCdelta tyrosine phosphorylation and enzymatic activity. Both inhibitors also reversed PPARgamma ligand effects on p21(Cip1) expression in PDGF-treated RASMC. PPARgamma ligands enhanced protein-tyrosine-phosphatase activity in RASMC, which may be the mechanism for decreased PKCdelta tyrosine phosphorylation and activity. PPARgamma ligands regulate p21(Cip1) at a post-translational level by blocking PKCdelta signaling and accelerating p21(Cip1) turnover.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11598137     DOI: 10.1074/jbc.M108719200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Novel diacylglycerol kinase inhibitor selectively suppressed an U46619-induced enhancement of mouse portal vein contraction under high glucose conditions.

Authors:  Koji Nobe; Mari Miyatake; Hiromi Nobe; Yasushi Sakai; Junko Takashima; Kazutaka Momose
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

Review 2.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

3.  Protein kinase C-delta regulates migration and proliferation of vascular smooth muscle cells through the extracellular signal-regulated kinase 1/2.

Authors:  Bo Liu; Evan Joseph Ryer; Rishi Kundi; Kentaro Kamiya; Hiroyuki Itoh; Peter L Faries; Kenji Sakakibara; K Craig Kent
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

4.  Rosiglitazone, a Peroxisome Proliferator-Activated Receptor (PPAR)-γ Agonist, Attenuates Inflammation Via NF-κB Inhibition in Lipopolysaccharide-Induced Peritonitis.

Authors:  Yun-Fang Zhang; Xun-Liang Zou; Jun Wu; Xue-Qing Yu; Xiao Yang
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

Review 5.  PPARγ Regulation in Hypertension and Metabolic Syndrome.

Authors:  Madeliene Stump; Masashi Mukohda; Chunyan Hu; Curt D Sigmund
Journal:  Curr Hypertens Rep       Date:  2015-12       Impact factor: 5.369

6.  Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation.

Authors:  Nancy Vázquez; Teresa Greenwell-Wild; Nancy J Marinos; William D Swaim; Salvador Nares; David E Ott; Ulrich Schubert; Peter Henklein; Jan M Orenstein; Michael B Sporn; Sharon M Wahl
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

Authors:  Georg Hansmann; Vinicio A de Jesus Perez; Tero-Pekka Alastalo; Cristina M Alvira; Christophe Guignabert; Janine M Bekker; Stefan Schellong; Takashi Urashima; Lingli Wang; Nicholas W Morrell; Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

8.  Involvement of PPAR-gamma and p53 in DHA-induced apoptosis in Reh cells.

Authors:  Hamid Zand; Ali Rhimipour; Masoomeh Bakhshayesh; Mohammad Shafiee; Issa Nour Mohammadi; Saideh Salimi
Journal:  Mol Cell Biochem       Date:  2007-05-09       Impact factor: 3.396

9.  PPAR gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms.

Authors:  Jane E Ward; Haslinda Gould; Trudi Harris; John V Bonacci; Alastair G Stewart
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

Review 10.  PPARs and the cardiovascular system.

Authors:  Milton Hamblin; Lin Chang; Yanbo Fan; Jifeng Zhang; Y Eugene Chen
Journal:  Antioxid Redox Signal       Date:  2009-06       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.